{"title":"多西他赛作为一线治疗高危激素敏感转移性前列腺癌患者的疗效和安全性","authors":"M. Stankovic","doi":"10.52768/2833-2725/1172","DOIUrl":null,"url":null,"abstract":"Purpose: To report the survival benefit, the course of disease and side effects in high-risk patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with first-line docetaxel.","PeriodicalId":108891,"journal":{"name":"Open Journal of Clinical and Medical Images","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of docetaxel as first line therapy in high-risk hormone sensitive metastatic prostate cancer patients\",\"authors\":\"M. Stankovic\",\"doi\":\"10.52768/2833-2725/1172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To report the survival benefit, the course of disease and side effects in high-risk patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with first-line docetaxel.\",\"PeriodicalId\":108891,\"journal\":{\"name\":\"Open Journal of Clinical and Medical Images\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Journal of Clinical and Medical Images\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52768/2833-2725/1172\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Journal of Clinical and Medical Images","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52768/2833-2725/1172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Efficacy and safety of docetaxel as first line therapy in high-risk hormone sensitive metastatic prostate cancer patients
Purpose: To report the survival benefit, the course of disease and side effects in high-risk patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with first-line docetaxel.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
